ZBIO at a glance
Zenas BioPharma, Inc. (ZBIO, SEC CIK 1953926) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Zenas BioPharma, Inc. (ZBIO) reported revenue of $10.0 million (up 100.0% from FY2024) and a net loss of $377.7 million. Diluted EPS was -$8.44.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Zenas BioPharma, Inc. (ZBIO) shares worth $319.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.0M
- +100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $319.1M · +0 vs prior quarter
- Latest 8-K
- Nov 6, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: April 2026 U.S. tariffs on patented pharmaceutical products, potentially increasing imported obexelimab costs
- China supply-chain exposure: WuXi Biologics remains sole obexelimab CMO, with imports subject to existing tariffs
- Debt-servicing risk: Operations are not expected to generate sufficient cash flow to service debt and fund capital expenditures
- Convertible-note liquidity risk: Required cash settlements upon conversion could materially reduce liquidity
- Maturity risk: Loan Agreement matures in 2031, requiring refinancing or repayment capacity then
Management Discussion & Analysis
- Revenue $10.0M, up from $0, driven by BMS development and regulatory milestone
- Net loss $108.9M vs $51.5M YoY, operating margin -1,034.1% vs not meaningful
- R&D $58.5M, led by obexelimab $22.6M and orelabrutinib $12.9M
- Cash, equivalents and investments $647.1M, operating cash outflow $190.4M for nine months
- Outlook: cash runway into 2029, with SLE topline results expected Q4 2026 and tariff-related cost headwinds
AI summary of the ZBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- New ATM program permits up to $200 million in additional common-stock sales
- Prior $200 million ATM terminated after approximately $153.2 million sold
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- FDA review of obexelimab IgG4-RD BLA targets May 27, 2027, while EMA validated the MAA, advancing dual-market commercialization
- Cash, equivalents and investments $647.1M, with projected funding through second quarter 2029 assuming $75M milestone and $75M debt draw
Item EX-99.1: Item EX-99.1
- Phase 3 extension showed 12-month flare-free probability of 0.93, supporting sustained obexelimab activity in IgG4-RD
- Obexelimab reduced cumulative glucocorticoid toxicity versus placebo, GTI difference -11.4, p=0.021, strengthening steroid-sparing rationale
Item 7.01: Regulation FD Disclosure
- New Phase 3 obexelimab data in IgG4-related disease, including open-label extension results
- Clinical update potentially informs efficacy durability and development prospects
AI summaries of ZBIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ZBIO
Don't miss the next ZBIO filing
- Alerts as it files. A push when ZBIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ZBIO, by share count.
- Ask anything. An AI agent that reads every ZBIO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Oliger Christy J. | A | Sep 1, 2026 | 37,000 | - |
| Allen Patricia L | A | Jun 15, 2026 | 18,500 | - |
| MOULDER LEON O JR | A | Jun 15, 2026 | 500,000 | - |
| Boylan James P | A | Jun 15, 2026 | 18,500 | - |
| Lu Hongbo | A | Jun 15, 2026 | 18,500 | - |
| Fox Jennifer A. | A | Jun 15, 2026 | 125,000 | - |
| ORLOFF JOHN J | A | Jun 15, 2026 | 18,500 | - |
| Farmer Joseph L | A | Jun 15, 2026 | 175,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $50.0M | $5.0M | $10.0M |
| Operating Income | - | -$163.9M | -$383.1M |
| Net Income | - | -$157.0M | -$377.7M |
| Op. Margin | - | -3277.8% | -3830.6% |
| Net Margin | - | -3139.8% | -3777.4% |
| Balance Sheet | |||
| Total Assets | $68.2M | $370.0M | $383.6M |
| Equity | -$225.7M | $312.5M | $242.1M |
| ROE | - | -50.2% | -156.0% |
| Per Share | |||
| EPS | $-24.25 | $-11.89 | $-8.44 |
| Cash Flow | |||
| Operating CF | - | -$119.7M | -$172.3M |
| CapEx | - | $131K | $18K |
Source: XBRL data in Zenas BioPharma, Inc. (ZBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ZBIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $319.1M |
| Q2 2026 | 23 | $532.4M |
| Q1 2026 | 23 | $324.8M |
| Q4 2025 | 20 | $460.6M |
| Q3 2025 | 18 | $189.5M |
| Q2 2025 | 17 | $66.6M |
| Q1 2025 | 13 | $34.7M |
| Q4 2024 | 13 | $28.6M |
- BlackRock+646.5K (+24%)
- Goldman Sachs Group+503.5K (+186%)
- Vanguard Capital Management LLC+367.8K (+27%)
- Invesco Ltd+92.7K (+489%)
- Vanguard Portfolio Management LLC+79.3K (+26%)
- Bank of America Corp−547.9K (-44%)
- Millennium Management−466.4K (-71%)
- State Street Corp−172.5K (-8%)
- T. Rowe Price Group−139.0K (-11%)
- Wells Fargo & Co−14.9K (-57%)
- Ameriprise Financial+13.9K
- Prudential Financial+9.9K
- FMR LLC (Fidelity)−9.51M
- Citadel Advisors LLC−195.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 150 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ZBIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| SC 13G | Sep 8, 2026 | - | - | |
| 4 | Sep 2, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13D | May 5, 2026 | - | - | |
| 4 | Apr 29, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ZBIO SEC filings: frequently asked questions
Which institutions hold ZBIO stock?
As of September 30, 2026, the largest Zenas BioPharma, Inc. (ZBIO) holders among the 13F filers tracked by SignalX were BlackRock ($89.9 million), State Street Corp ($50.8 million), Vanguard Capital Management LLC ($46.5 million), T. Rowe Price Group ($29.3 million), Two Sigma Investments ($22.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ZBIO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Zenas BioPharma, Inc. (ZBIO) reported revenue of $10.0 million (up 100.0% from FY2024) and a net loss of $377.7 million. Diluted EPS was -$8.44. The figures come from the XBRL data in the 10-K.
What did ZBIO report in its latest 8-K?
Zenas BioPharma, Inc. (ZBIO) filed an 8-K on November 6, 2026 reporting Item 8.01 (Other Events). New ATM program permits up to $200 million in additional common-stock sales.
What are the latest ZBIO SEC filings?
Zenas BioPharma, Inc. (ZBIO) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on September 2, 2026.
What is ZBIO's SEC CIK number?
Zenas BioPharma, Inc. (ZBIO)'s SEC Central Index Key (CIK) is 1953926. EDGAR lists every ZBIO filing under that number.
Ask anything about ZBIO
The research agent reads ZBIO's filings, financials, insider trades and 13F holders, then answers with sources.